DK2567709T3 - Molekyler og fremgangsmåder til modulering af lav-densitets-lipoprotein receptor-beslægtet protein 6 (LRP6) - Google Patents
Molekyler og fremgangsmåder til modulering af lav-densitets-lipoprotein receptor-beslægtet protein 6 (LRP6) Download PDFInfo
- Publication number
- DK2567709T3 DK2567709T3 DK12188230.2T DK12188230T DK2567709T3 DK 2567709 T3 DK2567709 T3 DK 2567709T3 DK 12188230 T DK12188230 T DK 12188230T DK 2567709 T3 DK2567709 T3 DK 2567709T3
- Authority
- DK
- Denmark
- Prior art keywords
- lrp6
- antibody
- binding
- antigen
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (10)
1. Monoklonalt antistof eller et antigen-bindende fragment deraf der specifikt binder til human lav-densitets-lipoprotein receptor-beslægtet protein 6 polypeptid (LRP6) med aminosyresekvensen af SEQ ID NO:l, er i stand til at antagonisere 5 Wnt-signaleringsvejen, og inhiberer Wnt3- og Wnt3a-specifik signaleringsaktivitet, hvor den antigen-bindende del binder til en epitop af humant LRP6 inde i aminosyrerne 631-932 af SEQ ID NO:l som vist i tabel 1.
2. Monoklonalt antistof eller antigen-bindende fragment ifolge krav 1, hvor den 10 antigen-bindende del er i stand til at binde til og inhibere phosphoryleret-LRP6 (phospho-LRP6).
3. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af de foregâende krav, hvor fragmentet er et Fab-fragment, et Fab'-fragment, et 15 F(ab')2-, eller et Fv-fragment af antistoffet.
4. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af de foregâende krav, hvor den antigen-bindende del binder til LRP6 med en Kd lig med eller mindre end 1 nM. 20
5. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af kravene 1-4, hvor den antigen-bindende del er en antigen-bindende del af et humant antistof.
6. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af kravene 1-4, hvor antistoffet er et humant eller humaniseret antistof.
7. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af kravene 1-5, hvor antistoffet er et kimært antistof. 30
8. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af de foregâende krav, hvor antistoffet er et af folgende isotyper: IgGl, IgG2, IgG3 eller IgG4.
9. Farmaceutisk sammensætning omfattende monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som helst af de foregâende krav.
10. Monoklonalt antistof eller antigen-bindende fragment ifolge et hvilket som 5 helst af kravene 1 til 8 eller den farmaceutiske sammensætning ifolge krav 9 til anvendelse i behandling af cancer, hvor anvendelsen omfatter administration af antistoffet, det antigen-bindende fragment, eller den farmaceutiske sammensætning til et individ der lider af eller er ramt af cancer. 10
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98482707P | 2007-11-02 | 2007-11-02 | |
EP08844924.4A EP2209491B1 (en) | 2007-11-02 | 2008-10-31 | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2567709T3 true DK2567709T3 (da) | 2018-03-12 |
Family
ID=40591553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12188230.2T DK2567709T3 (da) | 2007-11-02 | 2008-10-31 | Molekyler og fremgangsmåder til modulering af lav-densitets-lipoprotein receptor-beslægtet protein 6 (LRP6) |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100254980A1 (da) |
EP (3) | EP2209491B1 (da) |
JP (1) | JP5764329B2 (da) |
KR (1) | KR20100091170A (da) |
CN (1) | CN101951954A (da) |
AU (1) | AU2008320823B2 (da) |
BR (1) | BRPI0820327A2 (da) |
CA (1) | CA2700433A1 (da) |
DK (1) | DK2567709T3 (da) |
EA (1) | EA201000718A1 (da) |
ES (2) | ES2663077T3 (da) |
HK (1) | HK1252539A1 (da) |
MX (1) | MX2010004761A (da) |
PL (1) | PL2567709T3 (da) |
WO (1) | WO2009056634A2 (da) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143266A0 (en) | 1998-11-27 | 2002-04-21 | Darwin Discovery Ltd | Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same |
CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
EP2209491B1 (en) | 2007-11-02 | 2015-10-28 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
WO2009064944A2 (en) * | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
ES2341419B1 (es) * | 2008-08-14 | 2011-05-03 | Hospital Clinic I Provincial De Barcelona | Wnt1 como biomarcador de daño renal. |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
CN102985441B (zh) * | 2010-02-19 | 2015-04-22 | 俄克拉何马大学董事会 | 抑制Wnt信号传导途径的单克隆抗体及其制备方法和用途 |
BR112012022044A2 (pt) * | 2010-03-24 | 2020-08-25 | Genentech Inc | ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''. |
KR101441163B1 (ko) | 2010-04-05 | 2014-09-19 | 울산대학교 산학협력단 | 메갈린을 표적으로 하는 체중 조절 장애 관련 질환의 진단, 예방 또는 치료 방법 |
BR112012028326A2 (pt) * | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
EP4234698A3 (en) * | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
ME02819B (me) | 2010-05-14 | 2018-01-20 | Amgen Inc | Formulacije sa visokom koncentracijom antitijela |
ES2652363T3 (es) | 2010-08-18 | 2018-02-01 | Samumed, Llc | Dicetonas e hidroxicetonas como activadores de la vía de señalización de catenina |
US9133272B2 (en) | 2011-03-01 | 2015-09-15 | Amgen Inc. | Bispecific binding agents |
EA029956B1 (ru) | 2011-03-25 | 2018-06-29 | Эмджен Инк. | Кристаллы антител против склеростина и составы на их основе |
EP2508158B1 (en) | 2011-04-04 | 2014-07-02 | Arjo Hospital Equipment AB | Hoist apparatus |
EP2699261B1 (en) | 2011-04-19 | 2018-07-11 | Amgen Inc. | Method for treating osteoporosis |
US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
WO2012149246A1 (en) * | 2011-04-29 | 2012-11-01 | Novartis Ag | Methods of treating squamous cell carcinoma related applications |
WO2013019954A1 (en) | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
KR101399062B1 (ko) * | 2011-08-18 | 2014-05-27 | 한양대학교 산학협력단 | Wnt 유인 수용체를 포함하는 항암 조성물 |
CN109111523B (zh) * | 2011-10-14 | 2022-06-07 | 诺华股份有限公司 | 用于Wnt途径相关疾病的抗体和方法 |
EP3252075A1 (en) | 2011-11-04 | 2017-12-06 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
KR20190120401A (ko) | 2011-12-28 | 2019-10-23 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
WO2014029752A1 (en) * | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
EP2914279A4 (en) * | 2012-11-01 | 2016-07-06 | Univ Washington Ct Commerciali | MOLECULES, COMPOSITIONS AND METHODS FOR TREATING SCARING IN ORGANS |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US20190194314A1 (en) * | 2012-12-21 | 2019-06-27 | Stowers Institute For Medical Research | Antibodies for modulating binding between lrp and wise |
JP2016510411A (ja) * | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
RU2680716C2 (ru) | 2013-02-22 | 2019-02-26 | СЭМЬЮМЕД, ЭлЭлСи | γ-ДИКЕТОНЫ В КАЧЕСТВЕ АКТИВАТОРОВ WNT/β-КАТЕНИНОВОГО СИГНАЛЬНОГО ПУТИ |
CN105722525B (zh) * | 2013-11-13 | 2019-12-27 | 远东超级实验室有限公司 | 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途 |
CN103893781B (zh) * | 2014-04-10 | 2016-03-30 | 武汉大学 | Dickkopf-3(DKK3)基因在冠状动脉粥样硬化性心脏病中的功能和应用 |
EP3206686B1 (en) | 2014-08-20 | 2019-10-09 | Samumed, LLC | Gamma-diketones for treatment and prevention of aging skin and wrinkles |
EP3191526B1 (en) | 2014-09-12 | 2023-02-22 | The Board of Trustees of the Leland Stanford Junior University | Wnt signaling agonist molecules |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
SI3383425T1 (sl) | 2015-12-04 | 2020-11-30 | Boehringer Ingelheim International Gmbh | Biparatopični polipeptidi, ki antagonizirajo WNT-signaliziranje v tumorskih celicah |
MA43571A (fr) * | 2015-12-23 | 2018-11-14 | Biogen Ma Inc | Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP3496744A1 (en) | 2016-08-08 | 2019-06-19 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
EP3541423A4 (en) * | 2016-11-18 | 2020-10-07 | The Regents of The University of California | MODIFIED ANTIBODIES AND THEIR USES |
JP7037165B2 (ja) * | 2017-03-21 | 2022-03-16 | 国立大学法人東海国立大学機構 | 抗adamタンパク質基質抗体及びその利用 |
EP3732201A4 (en) | 2017-12-19 | 2022-04-20 | Surrozen Operating, Inc. | WNT SUBSTITUTION MOLECULES AND THEIR USES |
CN111699003B (zh) * | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
SG11202008206TA (en) | 2018-03-30 | 2020-09-29 | Amgen Inc | C-terminal antibody variants |
KR20210043607A (ko) | 2018-08-10 | 2021-04-21 | 암젠 인크 | 항체 제약 제형의 제조 방법 |
CN114630677A (zh) | 2019-08-12 | 2022-06-14 | 安进公司 | 抗硬骨素抗体配制品 |
US20220281969A1 (en) * | 2019-08-14 | 2022-09-08 | Modmab Therapeutics Inc. | Antibodies that bind to lrp6 proteins and methods of use |
CN114832106A (zh) * | 2022-03-25 | 2022-08-02 | 中山大学附属第七医院(深圳) | 靶向激活lrp6的工具在制备防治阿尔兹海默症药物中的应用 |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK1087013T3 (da) | 1992-08-21 | 2009-05-11 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
WO1994021293A1 (en) * | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
ATE332368T1 (de) | 1997-01-21 | 2006-07-15 | Gen Hospital Corp | Selektion von proteinen mittels rns-protein fusionen |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
US6267974B1 (en) | 1999-04-16 | 2001-07-31 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions with sensate mixtures based on isopulegol |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
EP2796546B1 (en) | 2001-04-19 | 2017-08-09 | The Scripps Research Institute | Incorporation of unnatural amino acids |
US7514594B2 (en) * | 2001-05-11 | 2009-04-07 | Wyeth | Transgenic animal model of bone mass modulation |
US7416849B2 (en) | 2001-05-11 | 2008-08-26 | Oscient Pharmaceuticals Corporation | HBM variants that modulate bone mass and lipid levels |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
IL158750A0 (en) * | 2001-05-17 | 2004-05-12 | Genome Therapeutics Corp | Reagents and methods for modulating dkk-mediated interactions |
WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
CN100560131C (zh) | 2001-10-22 | 2009-11-18 | 斯克里普斯研究学院 | 抗体靶向化合物 |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
CN1981054A (zh) * | 2004-05-14 | 2007-06-13 | 加利福尼亚大学董事会 | 用抗wnt2单克隆抗体和sirna治疗癌症的方法 |
KR20120133403A (ko) * | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
MX2007001221A (es) * | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
JP2008520583A (ja) * | 2004-11-15 | 2008-06-19 | マウント シナイ スクール オブ メディスン オブ ニューヨーク ユニバーシティー | Wnt自己分泌シグナル伝達を改変するための組成物および方法 |
WO2006089114A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating an anthrax toxin mediated condition |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2007140410A2 (en) * | 2006-05-30 | 2007-12-06 | Van Andel Research Institute | Low-density lipoprotein receptor 6 (lrp6) as a mammary stem cell marker and related methods |
EP2209491B1 (en) | 2007-11-02 | 2015-10-28 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
WO2009064944A2 (en) * | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
EP4234698A3 (en) * | 2010-05-06 | 2023-11-08 | Novartis AG | Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies |
BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
EP3252075A1 (en) * | 2011-11-04 | 2017-12-06 | Novartis AG | Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs |
-
2008
- 2008-10-31 EP EP08844924.4A patent/EP2209491B1/en not_active Revoked
- 2008-10-31 KR KR1020107009595A patent/KR20100091170A/ko not_active Application Discontinuation
- 2008-10-31 JP JP2010532556A patent/JP5764329B2/ja not_active Ceased
- 2008-10-31 MX MX2010004761A patent/MX2010004761A/es not_active Application Discontinuation
- 2008-10-31 ES ES12188230.2T patent/ES2663077T3/es active Active
- 2008-10-31 EP EP12188230.2A patent/EP2567709B1/en active Active
- 2008-10-31 ES ES08844924.4T patent/ES2560532T3/es active Active
- 2008-10-31 BR BRPI0820327-0A patent/BRPI0820327A2/pt not_active Application Discontinuation
- 2008-10-31 PL PL12188230T patent/PL2567709T3/pl unknown
- 2008-10-31 DK DK12188230.2T patent/DK2567709T3/da active
- 2008-10-31 EA EA201000718A patent/EA201000718A1/ru unknown
- 2008-10-31 US US12/740,134 patent/US20100254980A1/en not_active Abandoned
- 2008-10-31 CN CN2008801145208A patent/CN101951954A/zh active Pending
- 2008-10-31 AU AU2008320823A patent/AU2008320823B2/en not_active Ceased
- 2008-10-31 CA CA2700433A patent/CA2700433A1/en not_active Abandoned
- 2008-10-31 EP EP17196705.2A patent/EP3305324A1/en not_active Withdrawn
- 2008-10-31 WO PCT/EP2008/064821 patent/WO2009056634A2/en active Application Filing
-
2018
- 2018-09-14 HK HK18111852.4A patent/HK1252539A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008320823B2 (en) | 2013-01-17 |
EP2567709A3 (en) | 2013-05-08 |
EP2209491A2 (en) | 2010-07-28 |
JP2011503025A (ja) | 2011-01-27 |
ES2663077T3 (es) | 2018-04-11 |
WO2009056634A2 (en) | 2009-05-07 |
EP2567709A2 (en) | 2013-03-13 |
BRPI0820327A2 (pt) | 2020-10-06 |
EP2567709B1 (en) | 2017-12-27 |
EP2209491B1 (en) | 2015-10-28 |
US20100254980A1 (en) | 2010-10-07 |
EA201000718A1 (ru) | 2011-06-30 |
PL2567709T3 (pl) | 2018-06-29 |
JP5764329B2 (ja) | 2015-08-19 |
AU2008320823A1 (en) | 2009-05-07 |
HK1252539A1 (zh) | 2019-05-31 |
EP3305324A1 (en) | 2018-04-11 |
CA2700433A1 (en) | 2009-05-07 |
MX2010004761A (es) | 2010-05-19 |
CN101951954A (zh) | 2011-01-19 |
ES2560532T3 (es) | 2016-02-19 |
WO2009056634A3 (en) | 2009-12-10 |
KR20100091170A (ko) | 2010-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2567709T3 (da) | Molekyler og fremgangsmåder til modulering af lav-densitets-lipoprotein receptor-beslægtet protein 6 (LRP6) | |
US20180194846A1 (en) | Compositions and methods for increasing muscle growth | |
US9365651B2 (en) | Method for treating metabolic disorders by administration of an anti-ActRIIB antibody | |
US20090175875A1 (en) | Molecules and Methods for Modulating Complement Component | |
JP2010523135A (ja) | プロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)を調整する分子および方法 | |
US11834508B2 (en) | Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibody | |
AU2013204217A1 (en) | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |